Immtech, Par Halt Pafuramidine Development For HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision follows abnormal kidney function events in Phase I trial, December FDA clinical hold.
You may also be interested in...
Par Adds To HIV Portfolio With Immtech’s Pafuramidine
Par is projecting a late 2007 or early 2008 NDA submission for pneumocystis pneumonia in AIDS, the firm tells “The Pink Sheet” DAILY.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.